Portfolio

PHARMA - HAEMATO AG

HAEMATO AG is a pharmaceutical company whose focus lies on the growth markets of patent free and patent protected medicinal products. With its offer of generics, parallel and re-imports especially for the therapies of cancer, HIV and other chronic diseases, HAEMATO contributes actively towards cutting costs in the German healthcare system.

The HAEMATO AG is listed in the Entry Standard on the Frankfurt Stock Exchange under ISIN DE0006190705 / WKN 619070.

The company’s strategy of HAEMATO AG is hardly susceptible to cyclical or market fluctuations. Therefore we have achieved and will achieve high increases in value.

Following the takeover of HAEMATO AG (formerly Windsor AG) and the successful integration of HAEMATO PHARM GmbH in the year 2012, the share price of HAEMATO AG could be more than doubled. Moreover, the company is pursuing a shareholder-friendly dividend policy.

HEALTHCARE SERVICES - M1 KLINIKEN AG

M1 Kliniken AG is focused on the medicinal beauty market. With its products and services “Made in Germany” the group enables an affordable access to aesthetic medicine.

Besides a comprehensive offer of medical aesthetic treatments, the group develops and sells pharmaceutical and medical products and services as well as medical devices for the aesthetic surgery and cosmetic dermatology.

In the field of medical aesthetic treatments M1 Kliniken AG has already established itself as the market leader in Berlin.

M1 Kliniken AG was successfully brought on the stock market by MPH AG as of September 14, 2015. The shares have since been traded in the Entry Standard on the Frankfurt Stock Exchange under ISIN DE000A0STSQ8/WKN A0STSQ.

GROWTH INITIATIVES - MPH VENTURES

In the corporate division of MPH Ventures we invest in growth initiatives. In this field we do not exclusively confine ourselves to the healthcare market, but are open to all high growth industries.

Currently this area comprises the participations in Pharmigon GmbH, a company specialised in cytostatic admixture and concomitant medications, as well as in the real estate company CR Capital Real Estate AG.